| Literature DB >> 34980185 |
Judy M Luu1, Catherine Gebhard2,3, Chinthanie Ramasundarahettige4,5, Dipika Desai4, Karleen Schulze4,5, Francois Marcotte6, Philip Awadalla7, Philippe Broet8,9, Trevor Dummer10, Jason Hicks11, Eric Larose12, Alan Moody13, Eric E Smith14, Jean-Claude Tardif6, Tiago Teixeira15, Koon K Teo4,5,16, Jennifer Vena17, Douglas S Lee18,19, Sonia S Anand4,5,16, Matthias G Friedrich20.
Abstract
BACKGROUND: Despite the growing utility of cardiovascular magnetic resonance (CMR) for cardiac morphology and function, sex and age-specific normal reference values derived from large, multi-ethnic data sets are lacking. Furthermore, most available studies use a simplified tracing methodology. Using a large cohort of participants without history of cardiovascular disease (CVD) or risk factors from the Canadian Alliance for Healthy Heart and Minds, we sought to establish a robust set of reference values for ventricular and atrial parameters using an anatomically correct contouring method, and to determine the influence of age and sex on ventricular parameters. METHODS ANDEntities:
Keywords: Age; Cardiovascular magnetic resonance; Normal; Reference; Sex
Mesh:
Year: 2022 PMID: 34980185 PMCID: PMC8722350 DOI: 10.1186/s12968-021-00819-z
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1A typical example of an automatically generated contour (left) and the result of manual correction (right)
Fig. 2Measurement of left ventricular (LV) mass at end-systole. The systolic phase is used for quantification of LV mass; irregular surface and contour because of trabeculations during diastole (left) are less pronounced during systole (right)
Baseline demographics by sex and age groups for healthy participants (n = 3206)
| Baseline variables | Age < 55 years | 55 < = Age < 65 years | Age ≥ 65 years | Overall | p-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Female | Male | Female | Male | Female | Male | Female | Male | ||
| n = 972 | n = 549 | n = 795 | n = 383 | n = 313 | n = 194 | n = 2080 | n = 1126 | ||
| Age, years | 47.9 (4.7) | 47.6 (4.8) | 59.1 (2.8) | 59.1 (2.9) | 68.2 (2.5) | 68.2 (2.6) | 55.2 (8.4) | 55.1 (8.8) | 0.57 |
| Body weight (kg) | 64.0 (9.2) | 79.5 (9.8) | 62.9 (9.2) | 77.7 (10.0) | 62.3 (9.8) | 75.3 (10.0) | 63.3 (9.3) | 78.2 (10.0) | < 0.001 |
| Height (cm) | 164.3 (6.2) | 177.8 (7.0) | 162.6 (6.5) | 175.7 (7.0) | 161.5 (6.9) | 174.9 (6.2) | 163.2 (6.5) | 176.6 (7.0) | < 0.001 |
| BMI | 23.7 (2.9) | 25.1 (2.5) | 23.7 (2.9) | 25.1 (2.4) | 23.8 (3.0) | 24.6 (2.7) | 23.7 (2.9) | 25.0 (2.5) | < 0.001 |
| BMI > 30 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Percent body fat | 30.9 (6.5) | 20.7 (5.3) | 31.9 (6.6) | 21.5 (5.3) | 32.7 (7.2) | 22.0 (5.7) | 31.5 (6.7) | 21.2 (5.4) | < 0.001 |
| Waist circumference (cm) | 77.0 (8.7) | 87.0 (8.4) | 78.1 (9.0) | 88.8 (8.4) | 78.5 (9.3) | 89.1 (9.0) | 77.6 (8.9) | 87.9 (8.5) | < 0.001 |
| hip circumference (cm) | 96.3 (8.5) | 98.2 (6.9) | 96.0 (8.2) | 97.8 (5.9) | 96.5 (8.2) | 98.0 (6.3) | 96.2 (8.4) | 98.0 (6.5) | < 0.001 |
| Systolic blood pressure | 114.2 (10.9) | 122.2 (9.6) | 117.9 (11.4) | 124.4 (9.6) | 121.1 (11.0) | 125.5 (9.6) | 116.6 (11.4) | 123.5 (9.7) | < 0.001 |
| Diastolic blood pressure | 73.9 (7.6) | 77.1 (7.1) | 74.2 (7.8) | 76.6 (7.4) | 73.0 (8.0) | 76.3 (7.3) | 73.9 (7.8) | 76.8 (7.2) | < 0.001 |
| Heart rate | 69.7 (9.7) | 67.0 (10.2) | 69.7 (9.6) | 65.6 (10.1) | 70.8 (10.0) | 67.8 (11.0) | 69.9 (9.7) | 66.7 (10.3) | < 0.001 |
| Family history of cardiac disease | 184 (18.9%) | 73 (13.3%) | 195 (24.5%) | 83 (21.7%) | 79 (25.2%) | 40 (20.6%) | 458 (22.0%) | 196 (17.4%) | 0.00 |
| Ethnic background | |||||||||
| White Caucasian | 733 (75.4%) | 403 (73.4%) | 610 (76.7%) | 296 (77.3%) | 261 (83.4%) | 162 (83.5%) | 1604 (77.1%) | 861 (76.5%) | 0.15 |
| South Asian | 43 (4.4%) | 31 (5.6%) | 23 (2.9%) | 18 (4.7%) | 4 (1.3%) | 4 (2.1%) | 70 (3.4%) | 53 (4.7%) | |
| Chinese | 171 (17.6%) | 103 (18.8%) | 142 (17.9%) | 64 (16.7%) | 43 (13.7%) | 26 (13.4%) | 356 (17.1%) | 193 (17.1%) | |
| Other | 25 (2.6%) | 12 (2.2%) | 20 (2.5%) | 5 (1.3%) | 5 (1.6%) | 2 (1.0%) | 50 (2.4%) | 19 (1.7%) | |
| Medications | |||||||||
| Aspirin | 15 (1.5%) | 15 (2.7%) | 29 (3.6%) | 30 (7.8%) | 19 (6.1%) | 18 (9.3%) | 63 (3.0%) | 63 (5.6%) | < 0.001 |
| Statin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Values reported are mean (SD)
BMI body mass index
Biventricular and left atrial reference values for healthy males (n = 1126) and females (n = 2080) indexed to body surface area (BSA)
| CMR variables | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | 95% CI* | Normal range | Mean ± SD | 95% CI* | Normal range | |||
| Lower limit | Upper limit | Lower limit | Upper limit | |||||
| LVEF (%) | 62 ± 6 | 62 | 62 | 50–73 | 64 ± 6 | 64 | 65 | 53–76 |
| LVSV, indexed to BSA (ml/m2) | 46 ± 8 | 45 | 46 | 29–62 | 42 ± 7 | 42 | 42 | 28–56 |
| LVEDV, indexed to BSA (ml/m2) | 74 ± 13 | 73 | 75 | 48–100 | 65 ± 11 | 65 | 66 | 45–86 |
| LVESV, indexed to BSA (ml/m2) | 28 ± 7 | 28 | 29 | 14–43 | 23 ± 6 | 23 | 24 | 12–35 |
| LV mass, indexed to BSA (g/m2) | 61 ± 10 | 60 | 61 | 42–80 | 48 ± 8 | 47 | 48 | 33–62 |
| LV mass to volume ratio (g/ml) | 0.84 ± 0.16 | 0.83 | 0.848 | 0.53–1.15 | 0.74 ± 0.13 | 0.732 | 0.743 | 0.48–1.00 |
| RVEF (%) | 53 ± 6 | 53 | 53 | 41–65 | 58 ± 6 | 58 | 58 | 46–70 |
| RVSV, indexed to BSA (ml/m2) | 45 ± 8 | 45 | 46 | 29–62 | 42 ± 7 | 41 | 42 | 28–56 |
| RVEDV, indexed to BSA (ml/m2) | 86 ± 16 | 85 | 87 | 54–119 | 72 ± 13 | 72 | 73 | 47–8 |
| RVESV, indexed to BSA (ml/m2) | 41 ± 11 | 40 | 42 | 20–62 | 31 ± 8 | 30 | 31 | 14–47 |
| Min. LA volume, indexed to BSA (ml/m2) | 21 ± 7 | 21 | 21 | 7–35 | 19 ± 6 | 19 | 19 | 7–31 |
| Max. LA volume, indexed to BSA (ml/m2) | 39 ± 10 | 38 | 39 | 18–59 | 37 ± 9 | 36 | 37 | 19–54 |
| LA EF (%) | 46 ± 10 | 46 | 47 | 26–66 | 49 ± 11 | 48 | 49 | 28–70 |
| LA SV, indexed to BSA (ml/m2) | 18 ± 6 | 17 | 18 | 6–30 | 18 ± 6 | 18 | 18 | 7–29 |
LV Left ventricular; RV right ventricular; EF ejection fraction; SV stroke volume; EDV end-diastolic volume; ESV end-systolic volume; LA left atrium; Min minimum; Max maximum. Normal reference ranges are defined as the 95% prediction interval
Study cohort—excluded subjects with history of CVD or with risk factors of CVD -hypertension, diabetes, obesity, smoking or dyslipidemia
History of CVD—Aortic stenosis, Atrial fibrillation, Heart failure, Mitral stenosis, Previous PCI, Previous CABG, Valve surgery, TAVI, Hx of myocardial infarction
Reference ranges were calculated based on the formulae mean ± t0.975,n−1*sqrt[(n + 1)/n]*SD
*CI calculated based on the SE
**p value for testing Male vs Female
Biventricular and left atrial reference values indexed to BSA for males age 35 to 75 years, stratified by 10-year age categories
| CMR variables | 35 ≤ Age < 45 years | 45 ≤ Age < 55 years | 55 < = Age < 65 years | 65 ≤ Age < 75 years |
|---|---|---|---|---|
| LVEF, % | 61 ± 6 (49–73) | 62 ± 6 (50–73) | 62 ± 6 (51–73) | 62 ± 6 (50–75) |
| LVSV, indexed to BSA (ml/m2) | 47 ± 8 (30–64) | 46 ± 8 (30–62) | 46 ± 8 (30–62) | 43 ± 8 (26–59) |
| LVEDV, indexed to BSA (ml/m2) | 77 ± 13 (50–103) | 75 ± 13 (50–100) | 74 ± 13 (48–100) | 69 ± 13 (44–94) |
| LVESV, indexed to BSA (ml/m2) | 30 ± 8 (15–46) | 29 ± 7 (15–43) | 28 ± 7 (14–43) | 26 ± 7 (12–40) |
| LV mass, indexed to BSA (g/m2) | 61 ± 11 (40–82) | 61 ± 10 (42–80) | 62 ± 10 (43–81) | 58 ± 9 (40–75) |
| LV mass to volume ratio (g/ml) | 0.81 ± 0.13 (0.54–1.07) | 0.83 ± 0.15 (0.53–1.13) | 0.85 ± 0.15 (0.56–1.14) | 0.86 ± 0.20 (0.47–1.26) |
| RVEF, % | 51 ± 6 (39–64) | 53 ± 6 (41–64) | 53 ± 6 (41–66) | 54 ± 6 (41–66) |
| RVSV, indexed to BSA (ml/m2) | 46 ± 9 (29–64) | 46 ± 8 (30–62) | 46 ± 8 (29–62) | 43 ± 8 (26–59) |
| RVEDV, indexed to BSA (ml/m2) | 91 ± 18 (56–126) | 88 ± 16 (57–118) | 86 ± 17 (54–119) | 80 ± 15 (50–110) |
| RVESV, indexed to BSA (ml/m2) | 45 ± 12 (21–69) | 42 ± 10 (22–61) | 41 ± 11 (19–63) | 37 ± 10 (18–57) |
| Min. LA volume, indexed to BSA (ml/m2) | 19 ± 6 (8–30) | 20 ± 6 (8–33) | 22 ± 8 (7–37) | 21 ± 8 (5–37) |
| Max. LA volume, indexed to BSA (ml/m2) | 36 ± 9 (17–54) | 38 ± 10 (18–58) | 40 ± 10 (20–61) | 38 ± 11 (15–60) |
| LA SV, indexed to BSA (ml/m2) | 46 ± 10 (27–65) | 47 ± 10 (26–67) | 46 ± 10 (27–65) | 45 ± 11 (22–67) |
| LA EF (%) | 17 ± 6 (5–28) | 18 ± 6 (6–30) | 19 ± 6 (7–31) | 17 ± 6 (5–28) |
Values are for males (n = 1126; age 35 to 75 years) reported as mean ± SD (normal range), stratified by 10-year categories. Indexed values are normalized to BSA. Normal reference ranges are defined as the 95% prediction interval (see Methods section for calculation)
Study cohort—excluded subjects with history of CVD or with risk factors of CVD -hypertension, diabetes, obesity, smoking or dyslipidemia
History of CVD—Aortic stenosis, Atrial fibrillation, Heart failure, Mitral stenosis, Previous PCI, Previous CABG, Valve surgery, TAVI, Hx of myocardial infarction
Reference ranges were calculated based on the formulae mean ± t0.975,n−1*sqrt[(n + 1)/n]*SD
LV Left ventricular; RV right ventricular; EF ejection fraction; SV stroke volume; EDV end-diastolic volume; ESV end-systolic volume; LA left atrium; Min minimum; Max maximum
*p value for testing if all the means are equal
Ventricular and atrial reference values indexed to BSA for females age 35 to 75 years, stratified by 10-year age categories
| CMR variables | 35 ≤ Age < 45 years | 45 ≤ Age < 55 years | 55 < = Age < 65 years | 65 ≤ Age < 75 years |
|---|---|---|---|---|
| LVEF, % | 64 ± 5 (53–74) | 64 ± 5 (54–75) | 64 ± 6 (53–76) | 65 ± 6 (54–77) |
| LVSV, indexed to BSA (ml/m2) | 45 ± 7 (30–59) | 43 ± 7 (29–57) | 41 ± 7(28–55) | 40 ± 6 (28–52) |
| LVEDV, indexed to BSA (ml/m2) | 70 ± 11 (49–91) | 67 ± 10 (47–88) | 64 ± 10 (44–84) | 62 ± 9 (44–79) |
| LVESV, indexed to BSA (ml/m2) | 25 ± 6 (14–37) | 24 ± 6 (13–35) | 23 ± 6 (11–34) | 21 ± 5 (11–32) |
| LV mass, indexed to BSA (g/m2) | 48 ± 7 (33–62) | 47 ± 8 (32–63) | 48 ± 7 (33–63) | 46 ± 8 (31–62) |
| LV mass to volume ratio (g/ml) | 0.69 ± 0.11 (0.47–0.91) | 0.72 ± 0.12 (0.47–0.96) | 0.76 ± 0.14 (0.50–1.03) | 0.76 ± 0.14 (0.49–1.04) |
| RVEF, % | 56 ± 6 (45–68) | 58 ± 6 (46–69) | 58 ± 7 (45–71) | 59 ± 6 (47–72) |
| RVESV, indexed to BSA (ml/m2) | 44 ± 7 (30–59) | 43 ± 7 (28–57) | 41 ± 7 (27–54) | 39 ± 6 (27–52) |
| RVEDV, indexed to BSA (ml/m2) | 79 ± 13 (53–105) | 74 ± 13 (49–100) | 71 ± 13 (46–96) | 67 ± 11 (46–88) |
| RVESV, indexed to BSA (ml/m2) | 35 ± 8 (18–52) | 32 ± 8 (16–48) | 30 ± 8 (13–47) | 28 ± 7 (14–42) |
| Min. LA volume, indexed to BSA(ml/m2) | 17 ± 5 ( 6–27) | 18 ± 6 (7–29) | 19 ± 6 (7–32) | 21 ± 7 (7–34) |
| Max. LA volume, indexed to BSA(ml/m2) | 34 ± 8 (19–50) | 37 ± 9 (20–54) | 37 ± 9 (19–55) | 38 ± 9 (20–57) |
| LA SV, indexed to BSA(ml/m2) | 52 ± 11 (30–73) | 50 ± 10 (30–71) | 48 ± 11 (26–69) | 47 ± 10 (27–67) |
| LA EF (%) | 18 ± 5 ( 7–28) | 18 ± 6 (7–30) | 18 ± 6 (6–29) | 18 ± 6 (7–29) |
Values are for females (n = 2080, age 35 to 75 years), reported as mean ± SD (normal range), stratified by 10-year categories. Indexed values are normalized to BSA. Normal reference ranges are defined as the 95% prediction interval
Study cohort—excluded subjects with history of CVD or with risk factors of CVD -hypertension, diabetes, obesity, smoking or dyslipidemia
History of CVD—Aortic stenosis, Atrial fibrillation, Heart failure, Mitral stenosis, Previous PCI, Previous CABG, Valve surgery, TAVI, Hx of myocardial infarction
Reference ranges were calculated based on the formulae mean ± t0.975,n−1*sqrt[(n + 1)/n]*SD
LV Left ventricular; RV right ventricular; EF ejection fraction; SV stroke volume; EDV end-diastolic volume; ESV end-systolic volume; LA left atrium; Min minimum; Max maximum
*p value for testing if all the means are equal
Intraclass correlation coefficient for inter-observer and intra-observer variability of CMR data
| Intra-observer reliability readers randoma | Inter-observer reliability readers randoma | |
|---|---|---|
| LVEDV | 0.88 | 0.92 |
| LVESV | 0.83 | 0.85 |
| LVSV | 0.85 | 0.87 |
| LVEF | 0.72 | 0.61 |
| RVEDV | 0.87 | 0.90 |
| RVESV | 0.90 | 0.90 |
| RVSV | 0.81 | 0.86 |
| RVEF | 0.86 | 0.83 |
aReaders are a representative of a large population of readers
LV Left ventricular; RV right ventricular; EF ejection fraction; SV stroke volume; EDV end-diastolic volume; ESV end-systolic volume
Comparison between studies with CMR-derived normal reference values
| Study (Author, Journal Year) | Sample Size (n =) | Age (years) | Ethnicity | % Female representation (male:female) | Contouring Method | Mean LVEDV indexed to BSA (ml/m2) | Mean LVEF (%) |
|---|---|---|---|---|---|---|---|
| Current study, Luu et al. 2021 | 3206 | 35–75 | Multi-ethnic | 65% (1126:2080) | Inclusion of papillary muscle in LV mass | Female: 66 Male: 74 | Female: 65 Male: 62 |
| Petersen et al. JCMR 2017 | 800 | 45–74 | All Caucasians | 54% (368:432) | Inclusion of papillary muscle in LV volume | Female: 74 Male: 85 | Female: 61 Male: 58 |
| Lei et al., JMRI 2017 | 120 | 23–83 | All Han Chinese | 50% (60:60) | Inclusion of papillary muscle in LV volume | Female: 68.7 Male: 76.5 | Female: 67.1 Male: 64.6 |
| Le et al., JCMR 2016 | 180 | 20–69 | All Singaporean Chinese | 49% (91:89) | Inclusion of papillary muscle in LV mass | Female: 71 Male: 79 | Female: 62 Male: 58 |
| Yeon et al., JMRI 2015 | 852 | 38–88a | Most Caucasians | 60% (512:340) | Inclusion of papillary muscle in LV volume | Female: 62 Male: 71 | Female: 60.6 Male: 58.6 |
| Natori et al., AJR 2006 | 800 | 45–84 | Multi-ethnic | 50% (400:400) | Inclusion of papillary muscle in LV volume | Female: 64.5 Male: 73.9 | Female:71.8 Male: 67.2 |
| Maceira et al., JCMR 2006 | 120 | 20–80 | Not mentioned | 50% (60:60) | Inclusion of papillary muscle in LV mass | Female: 75 Male: 80 | Female: 67 Male: 67 |
| Hudsmith et al., JCMR 2005 | 108 | 21–68 | Not mentioned | 42% (63:45) | Inclusion of papillary muscle in LV mass | Female: 78 Male: 82 | Female: 69 Male: 69 |
| Alfakih et al., JMRI 2003 | 60 | 20–65 | Not mentioned | 50% (30:30) | Inclusion of papillary muscle in LV mass | Female: 77.7 Male: 82.3 | Female: 64.0 Male: 64.2 |
| Salton et al., JACC 2002 | 142 | 38–72 | Not mentioned | 56% (63:79) | Inclusion of papillary muscle in LV volume | Female: 49.8 Male: 57.6 | Female: 70 Male: 69 |
aAge range not reported in original publication, but study population clarified in the source by Oyama et al. 2008. “Differential Impact of Age, Sex, and Hypertension on Aortic Atherosclerosis.” Arteriosclerosis, Thrombosis, and Vascular Biology 28 (1): 155–59
LV left ventricular; LVEDV left ventricular end-diastolic volume; BSA body surface area; LVEF left ventricular ejection fraction
Fig. 3Anatomically correct contouring method for left ventricular (LV) mass. Papillary muscles and trabecular structures are included as myocardium (and not as blood) (right panel). Using the simplified method (left) of drawing the contour to define the arbitrary “cutoff” line (yellow arrows) may be subjected to additional observer variability and errors